eligibility_summary
Eligibility: Consent, R/R B‑NHL: DLBCL & WM (≥2 lines incl anthracycline+anti‑CD20+BTKi), FL 1–3a & MZL (≥2 lines incl anthracycline+anti‑CD20), MCL (≥2 lines incl anti‑CD20, anthracycline/bendamustine + BTKi), CLL resistant to BTKi & BCL2i, relapse/progression ≤24 mo (except MCL), ECOG 0–1, ANC ≥0.5, Plt ≥30, TBil ≤2×ULN, AST/ALT ≤3×ULN, CrCl ≥30. Exclude: recent malignancy/therapy, cardiac (QTc>480/LVEF<50%), hepatic/renal impairment, HIV/HBV/active infection, surgery ≤14 d, pregnancy, allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ib/II single-arm trial in relapsed/refractory B‑cell NHL combining: 1) Glofitamab—CD20×CD3 bispecific IgG T‑cell engager that links CD3 on T cells to CD20 on B cells to drive cytotoxicity (step‑up dosing, also used as post–CAR‑T maintenance), 2) Obinutuzumab—glycoengineered type II anti‑CD20 monoclonal antibody used as bridging/debulking to deplete CD20+ B cells and mitigate CRS, 3) Autologous CD19 CAR‑T cells after fludarabine/cyclophosphamide lymphodepletion (adoptive cellular therapy). Targets/pathways: CD20 on malignant B cells, CD19 on B cells, CD3/TCR activation on T cells, effector T‑cell cytotoxic pathways (including redirected killing via bispecifics) and B‑cell depletion (ADCC/ADCP/direct cell death). Study assesses safety and how bispecific maintenance dosing affects CAR‑T expansion/efficacy.